The TruSight Myeloid Sequencing Panel uses expert-defined content and proven next-generation sequencing (NGS) technology to identify somatic variants in myeloid malignancies. The TruSight Myeloid Sequencing Panel covers 15 full genes (exons only) and 39 additional genes where oncogenic hotspots are covered, providing a comprehensive assessment of the key genes known to be involved in myeloid malignancies in a single test.
Acute Myelogenous Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
ABL1 (ABL proto-oncogene 1), ASXL1 (ASXL Transcriptional Regulator 1), ATRX (ATRX Chromatin Remodeler), BCOR (BCL6 Corepressor), BRAF (B-raf proto-oncogene), CALR (Calreticulin)
See More ...
Next-Generation Sequencing (NGS)